Disease-A-Month
Volume 56, Issue 3 , Pages 163-179, March 2010

Updates on Cytochrome P450-Mediated Cardiovascular Drug Interactions

  • Judy W.M. Cheng, PharmD, MPH, FCCP, BCPS

      Affiliations

    • Arnold and Marie Schwartz College of Pharmacy and Sciences, Long Island University, Brooklyn, New York, Mt. Sinai Medical Center, New York, New York
    • ,
  • William H. Frishman, MD

      Affiliations

    • Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York
    • ,
  • Wilbert S. Aronow, MD

      Affiliations

    • Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York

Cytochrome P (CYP) 450 is a superfamily of hemoproteins that play an important role in the metabolism of steroid hormones, fatty acids, and many medications. Many agents used for management of cardiovascular diseases are substrates, inhibitors, or inducers of CYP450 enzymes. When two agents that are substrates, inhibitors, or inducers of CYP450 are administered together, drug interactions with significant clinical consequences may occur. This review discusses CYP450-mediated cardiovascular drug interactions as well as noncardiovascular drug interactions that produced significant cardiovascular side effects. The principles in predicting drug interactions are also discussed.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Reprinted with permission from Cheng JWM, Frishman WH, Aronow WS. Updates on Cytochrome P450-Mediated Cardiovascular Drug Interactions. Am J Ther 2009;16:155-63.

PII: S0011-5029(09)00159-X

doi:10.1016/j.disamonth.2009.12.011

Disease-A-Month
Volume 56, Issue 3 , Pages 163-179, March 2010

Article Tools